News & Events

Read the latest updates from MitoRx Therapeutics

  • The novel small molecule Myo4 normalises glycemic control, reduces weight/fat mass and prevents semaglutide-induced muscle remodelling in the murine diet-induced obesity model

    • Publication
    • Posted 12 May, 2025
    Read More

  • MitoRx Therapeutics appoints Xavier Jacq as CSO

    • Press Release
    • Posted 1 May, 2025
    Read More

  • MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director

    • Press Release
    • Posted 9 January, 2025
    Read More

  • MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity

    • Press Release
    • Posted 10 October, 2024
    Read More

  • MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme

    • Press Release
    • Posted 3 October, 2024
    Read More

  • MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

    • Press Release
    • Posted 7 March, 2024
    Read More

  • MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

    • Press Release
    • Posted 13 December, 2023
    Read More

  • MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.

    • Press Release
    • Posted 7 March, 2023
    Read More

  • MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

    • Press Release
    • Posted 25 April, 2022
    Read More